ストックスクリーナーアプリを入手
22.24
4.55%
-1.06
アフターアワーズ：
22.70
0.46
+2.07%
前日終値:
$23.30
開ける：
$23.3
24時間の取引高:
1.65M
Relative Volume:
2.40
時価総額：
$2.88B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.95%
1か月 パフォーマンス:
+14.82%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$19.90
$23.82
1週間の範囲:
$19.90
$23.82
52週間の値動き範囲:
$18.50
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Compare KLRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
22.24 | 3.02B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-05-12 | 開始されました | Evercore ISI | Outperform |
| 2026-05-12 | 開始されました | JP Morgan | Overweight |
| 2026-05-12 | 開始されました | Jefferies | Buy |
| 2026-05-12 | 開始されました | Leerink Partners | Outperform |
| 2026-05-12 | 開始されました | TD Cowen | Buy |
| 2026-05-12 | 開始されました | William Blair | Outperform |
すべてを表示
Kailera Therapeutics Inc (KLRA) 最新ニュース
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback - Investor's Business Daily
Kailera falls after late-stage trial data for oral GLP-1 candidate - Seeking Alpha
Kailera shares tumble on high nausea rates despite weight-loss drug's success - Reuters
Kailera reports 11.1% weight loss data - grafa.com
Kailera Therapeutics Announces Positive Topline Data From Two Hengrui Pharma Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 - marketscreener.com
Kailera’s obesity drug meets main goal of late-stage trials in China - 101 WIXX
Kailera says obesity pill succeeds in late-stage trial in China - Yahoo Finance
Kailera’s weight-loss drug meets main goal of late-stage trials in China - hi99.com
Kailera's weight-loss drug meets main goal of late-stage trials in China - marketscreener.com
Kailera’s GLP-1 drug meets main goal of late-stage trials - WTVB
Kailera's GLP-1 drug meets main goal of late-stage trials - Yahoo Finance
Kailera Therapeutics Announces Positive Topline Data from - GlobeNewswire
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Kailera Therapeutics (KLRA) Stock Looks Overvalued Despite Its 20% Slump - Yahoo Finance
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
Kailera appoints Kathleen Tregoning as chief corporate affairs officer - The Pharma Letter
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Index - marketscreener.com
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Value Benchmark - marketscreener.com
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - The Manila Times
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Press Release: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - Moomoo
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 3000E Value Benchmark - marketscreener.com
Kailera Therapeutics, Inc. (KLRA) Total Assets (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Gross Margin (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Net Income (TTM) - Zacks Investment Research
Enterprise value to revenue forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc. (KLRA) Return On Assets (TTM) - Zacks Investment Research
Price to sales forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc. (KLRA) Price Book Value - Zacks Investment Research
Price to book forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics (KLRA) Insider Trading Activity 2026 $KLRA - MarketBeat
Price to earnings forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to S&P TMI Index - marketscreener.com
Latest KLRA ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
KLRA Technical Analysis & ETF Price Forecast - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Kardigan surges in Nasdaq debut after upsized $400 million IPO - marketscreener.com
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Kailera Therapeutics, Inc. Common Stock (NASDAQ: KLRA) Stock Price, News & Analysis - Kalkine
This Stock Is Up 58% This Year. Is It too Late to Buy? - AOL.com
‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic? - Yahoo! Finance Canada
Parabilis sets biotech IPO record with $670M raise - MSN
Parabilis Is Now the Largest VC-Backed Biotech IPO - Morningstar
Kailera (KLRA) CEO exercises stock options, now holds 38,094 shares - Stock Titan
Parabilis now the largest VC-backed biotech IPO - Yahoo Finance
Parabilis Breaks Kailera’s Short-Lived Biopharma IPO Record - Citeline News & Insights
Parabilis sets a record with a $670M biotech IPO - BioPharma Dive
Parabilis takes top spot, pricing largest biopharma IPO at $670M - BioWorld News
Parabilis Medicines raises $670M in upsized IPO - Axios
Kailera Therapeutics Inc (KLRA) 財務データ
Kailera Therapeutics Inc (KLRA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Kailera Therapeutics Inc (KLRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
500,000 |
8,000,000 |
10,776,820 |
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):